This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (206)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Pathology & Laboratory Medicine  • Drug Therapy, Other  • Alert me on articles by topic

Robert M. Grant, MD, MPH; Frederick M. Hecht, MD; Maria Warmerdam, BS; Lea Liu, MD, MSc; Teri Liegler, PhD; Christos J. Petropoulos, PhD; Nicholas S. Hellmann, MD; Margaret Chesney, PhD; Michael P. Busch, MD; James O. Kahn, MD

JAMA. 2002;288:181-188.

Context  Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy.

Objective  To determine trends in prevalence of HIV-1 drug resistance among recently infected individuals in a geographic area with a high penetration of antiviral treatment.

Design, Setting, and Patients  Consecutive case series of 225 patients referred to a San Francisco, Calif, hospital with recent HIV-1 infection from June 1996 through June 2001.

Main Outcome Measure  Time trends in the prevalence of genotypic and phenotypic primary drug resistance.

Results  Mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) steadily increased from 0% in 1996-1997 to 12 (13.2%) in 2000-2001 (P = .01). There was 1 mutation associated with protease inhibitor resistance in 1996-1997 (2.5%) and there were 7 (7.7%) in 2000-2001 (P = .25). Genotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) initially decreased and then returned to prior levels (P = .007 for test of homogeneity). Genotypic resistance to 2 or more classes of drugs increased from 1 (2.5%) to 12 (13.2%) (P = .004), but only 1 infection (1.2%) in the latter period was resistant to all 3 classes of agents (P = .58). Primary phenotypic resistance decreased for NRTIs from 21% to 6.2% (P = .03) and increased for NNRTIs from 0 to 8 (9.9%) (P = .02). Phenotypic resistance increased for protease inhibitors from 2.6% to 6.2% (P = .32). Median time to virologic suppression (<500 copies/mL) during therapy was 12 weeks for patients with genotypic evidence of resistance compared with 5 weeks for patients with drug-sensitive infections (P = .02).

Conclusions  The frequency of primary resistance to NNRTIs is increasing, although resistance to all available classes of antiretroviral therapy remains rare. Genotypic resistance testing in recently infected persons predicts time to viral suppression during therapy.

Author Affiliations: Gladstone Institute of Virology and Immunology (Drs Grant and Liegler and Ms Warmerdam), Positive Health Program, San Francisco General Hospital (Drs Grant, Hecht, Liu, and Kahn), Center for AIDS Prevention Studies (Dr Chesney), Department of Medicine, University of California, San Francisco (Drs Grant, Hecht, Liu, Busch, and Kahn), Blood Centers of the Pacific (Dr Busch), San Francisco; and ViroLogic, South San Francisco, Calif (Drs Petropoulos and Hellmann).

RELATED ARTICLES

Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial
Scott M. Hammer, Florin Vaida, Kara K. Bennett, Mary K. Holohan, Lewis Sheiner, Joseph J. Eron, Lawrence Joseph Wheat, Ronald T. Mitsuyasu, Roy M. Gulick, Fred T. Valentine, Judith A. Aberg, Michael D. Rogers, Cheryl N. Karol, Alfred J. Saah, Ronald H. Lewis, Laura J. Bessen, Carol Brosgart, Victor DeGruttola, John W. Mellors, and for the AIDS Clinical Trials Group 398 Study Team
JAMA. 2002;288(2):169-180.
ABSTRACT | FULL TEXT  

Emerging Resistance to Nonnucleoside Reverse Transcriptase Inhibitors: A Warning and a Challenge
Joel D. Trachtenberg and Merle A. Sande
JAMA. 2002;288(2):239-241.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Activity of the Small Modified Amino Acid {alpha}-Hydroxy Glycineamide on In Vitro and In Vivo Human Immunodeficiency Virus Type 1 Capsid Assembly and Infectivity
Abdurahman et al.
Antimicrob. Agents Chemother. 2008;52:3737-3744.
ABSTRACT | FULL TEXT  

In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti-HIV Activity of Aplaviroc
Demarest et al.
J Clin Pharmacol 2008;48:1179-1188.
ABSTRACT | FULL TEXT  

Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006
Derache et al.
J Antimicrob Chemother 2008;62:456-463.
ABSTRACT | FULL TEXT  

The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men
Zaric et al.
Med Decis Making 2008;28:359-376.
ABSTRACT  

Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection
Little et al.
J. Virol. 2008;82:5510-5518.
ABSTRACT | FULL TEXT  

Integrating Multidimensional HIV Prevention Programs Into Healthcare Settings
Temoshok and Wald
Psychosom. Med. 2008;70:612-619.
ABSTRACT | FULL TEXT  

Highly Active Antiretroviral Therapy Use and HIV Transmission Risk Behaviors Among Individuals Who Are HIV Infected and Were Recently Released From Jail
Clements-Nolle et al.
Am. J. Public Health 2008;98:661-666.
ABSTRACT | FULL TEXT  

Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan
Chang et al.
J Antimicrob Chemother 2008;61:689-693.
ABSTRACT | FULL TEXT  

Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy
Ambrose et al.
J. Virol. 2007;81:12145-12155.
ABSTRACT | FULL TEXT  

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness
Dykes and Demeter
Clin. Microbiol. Rev. 2007;20:550-578.
ABSTRACT | FULL TEXT  

Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings
Taiwo and Murphy
J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:188-197.
ABSTRACT  

Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection
Booth and Geretti
J Antimicrob Chemother 2007;59:1047-1056.
ABSTRACT | FULL TEXT  

Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance
de Mendoza et al.
J Antimicrob Chemother 2007;59:698-704.
ABSTRACT | FULL TEXT  

Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting?
Truong et al.
Sex. Transm. Infect. 2006;82:461-466.
ABSTRACT | FULL TEXT  

Susceptibility of Human Testis to Human Immunodeficiency Virus-1 Infection in Situ and in Vitro
Roulet et al.
Am. J. Pathol. 2006;169:2094-2103.
ABSTRACT | FULL TEXT  

Investigation of a New Diagnosis of Multidrug-Resistant, Dual-Tropic HIV-1 Infection--New York City, 2005
JAMA 2006;296:1226-1228.
FULL TEXT  

Antiretroviral treatment of HIV infected adults.
Deeks
BMJ 2006;332:1489-1489.
FULL TEXT  

In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection
Gu et al.
Antimicrob. Agents Chemother. 2006;50:625-631.
ABSTRACT | FULL TEXT  

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
UK Group on Transmitted HIV Drug Resistance
BMJ 2005;331:1368.
ABSTRACT | FULL TEXT  

TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments
Vingerhoets et al.
J. Virol. 2005;79:12773-12782.
ABSTRACT | FULL TEXT  

Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist
Takashima et al.
Antimicrob. Agents Chemother. 2005;49:3474-3482.
ABSTRACT | FULL TEXT  

Low Proportion of Recent Human Immunodeficiency Virus (HIV) Infections among Newly Diagnosed Cases of HIV Infection as Shown by the Presence of HIV-Specific Antibodies of Low Avidity
Puchhammer-Stockl et al.
J. Clin. Microbiol. 2005;43:497-498.
ABSTRACT | FULL TEXT  

Comparison of Oligonucleotide Ligation Assay and Consensus Sequencing for Detection of Drug-Resistant Mutants of Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells and Plasma
Ellis et al.
J. Clin. Microbiol. 2004;42:3670-3674.
ABSTRACT | FULL TEXT  

Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine
Garcia-Lerma et al.
J. Virol. 2004;78:7545-7552.
ABSTRACT | FULL TEXT  

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
Bangsberg et al.
J Antimicrob Chemother 2004;53:696-699.
ABSTRACT | FULL TEXT  

Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
Gulick et al.
NEJM 2004;350:1850-1861.
ABSTRACT | FULL TEXT  

HIV Drug Resistance
Clavel and Hance
NEJM 2004;350:1023-1035.
FULL TEXT  

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing
Li et al.
Proc. Natl. Acad. Sci. USA 2003;100:13555-13560.
ABSTRACT | FULL TEXT  

Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why?
Katzenstein
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:140-146.
 

Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions
Guo et al.
J. Virol. 2003;77:10528-10536.
ABSTRACT | FULL TEXT  

Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection
Simon et al.
J. Virol. 2003;77:7736-7745.
ABSTRACT | FULL TEXT  

Accuracy of the TRUGENE HIV-1 Genotyping Kit
Grant et al.
J. Clin. Microbiol. 2003;41:1586-1593.
ABSTRACT | FULL TEXT  

More on Transmission of Drug-Resistant Virus
AIDS Clin Care 2002;2002:3-3.
FULL TEXT  

Mounting Rates of Drug Resistance in New HIV Infections
JWatch General 2002;2002:1-1.
FULL TEXT  

Increasing Drug Resistance in Acute HIV Infection in San Francisco
JWatch Infect. Diseases 2002;2002:4-4.
FULL TEXT  

Emerging Resistance to Nonnucleoside Reverse Transcriptase Inhibitors: A Warning and a Challenge
Trachtenberg and Sande
JAMA 2002;288:239-241.
FULL TEXT